Log in

Relevant bibliographies by topics / H. Lee Moffitt Cancer Center and Research Institute / Journal articles

To see the other types of publications on this topic, follow the link: H. Lee Moffitt Cancer Center and Research Institute.

Journal articles on the topic 'H. Lee Moffitt Cancer Center and Research Institute'

Author: Grafiati

Published: 4 June 2021

Last updated: 28 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'H. Lee Moffitt Cancer Center and Research Institute.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

C. Geppner, MLS, CTTS, PA-C, Alexis. "Targeting p53 in MDS: Highlights From SOHO 2021." Journal of the Advanced Practitioner in Oncology 13, no. 1 (2022): 15–16. http://dx.doi.org/10.6004/jadpro.2022.13.1.12.

Full text

Abstract:

Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, evaluates data from the session on p53 in myelodysplastic syndrome presented by David A. Sallman, MD, of H. Lee Moffitt Cancer Center and Research Institute, at the 2021 SOHO Annual Meeting.

APA, Harvard, Vancouver, ISO, and other styles

2

Sutphen, Rebecca, Yan Xu, George D. Wilbanks, et al. "Lysophospholipids Are Potential Biomarkers of Ovarian Cancer." Cancer Epidemiology, Biomarkers & Prevention 13, no. 7 (2004): 1185–91. http://dx.doi.org/10.1158/1055-9965.1185.13.7.

Full text

Abstract:

Abstract Objective: To determine whether lysophosphatidic acid (LPA) and other lysophospholipids (LPL) are useful markers for diagnosis and/or prognosis of ovarian cancer in a controlled setting. Method: Plasma samples were collected from ovarian cancer patients and healthy control women in Hillsborough and Pinellas counties, Florida, and processed at the University of South Florida H. Lee Moffitt Cancer Center and Research Institute (Moffitt). Case patients with epithelial ovarian cancer (n = 117) and healthy control subjects (n = 27) participated in the study. Blinded LPL analysis, including

APA, Harvard, Vancouver, ISO, and other styles

3

Albrecht, Terrance L., Christina Blanchard, John C. Ruckdeschel, Michael Coovert, and Rebecca Strongbow. "Strategic Physician Communication and Oncology Clinical Trials." Journal of Clinical Oncology 17, no. 10 (1999): 3324–32. http://dx.doi.org/10.1200/jco.1999.17.10.3324.

Full text

Abstract:

PURPOSE: Clinical trials are the primary means for determining new, effective treatments for cancer patients, yet the number of patients that accrue is relatively limited. The purpose of this study was to explore the relationship between physician behavior and patient accrual to a clinical trial by videotaping the interaction. PATIENTS AND METHODS: Forty-eight patient-physician interactions involving 12 different oncologists were videotaped in several clinics at the H. Lee Moffitt Cancer Center and Research Institute (Tampa, FL). The purpose of each interaction was to present the possibility o

APA, Harvard, Vancouver, ISO, and other styles

4

Walker-Mimms, Hannah L., Nicole Londono, Yi Liao, et al. "Abstract A060 Investigating underlying efficacy and mechanism of action of the KIF11 inhibitor filanesib in Ewing and clear cell sarcomas." Cancer Research 84, no. 17_Supplement (2024): A060. http://dx.doi.org/10.1158/1538-7445.pediatric24-a060.

Full text

Abstract:

Abstract Ewing (ES) and clear cell (CCS) sarcomas are bone and soft tissue malignances and in advanced and relapsed disease overall survival rates remain dismal. For metastatic ES, five-year survival rates are between 15% and 30%. In CCS, the five-year survival rates are between 30% and 67%. Accordingly, there is a critical need for the development of novel targeted therapeutics for the treatment of these rare cancers. Both cancers are driven by fusion proteins; EWS-FLI1 in ES and EWS-ATF1 in CCS, which arise from separate chromosomal translocations: t(11;22)(q24;q12) and t(12;22)(q13;q12) res

APA, Harvard, Vancouver, ISO, and other styles

5

Yacoub, Abraham Tareq, Jayasree Krishnan, Ileana M. Acevedo, Joseph Halliday, and John Norman Greene. "NUTRITIONALLY VARIANT STREPTOCOCCI BACTEREMIA IN CANCER PATIENTS: A RETROSPECTIVE STUDY, 1999-2014." Mediterranean Journal of Hematology and Infectious Diseases 7 (April 19, 2015): e2015030. http://dx.doi.org/10.4084/mjhid.2015.030.

Full text

Abstract:

BackgoundNutritionally variant Streptococci (NVS), Abiotrophia and Granulicatella are implicated in causing endocarditis and blood stream infections more frequently than other sites of infection. Neutropenia and mucositis are the most common predisposing factors for infection with other pathogens in cancer patients. In this study we investigated the clinical characteristics of NVS bacteremia in cancer patients and identified risk factors and outcomes associated with these infections. Materials and MethodsWe retrospectively reviewed all cases of NVS bacteremia occurring from June 1999 to April

APA, Harvard, Vancouver, ISO, and other styles

6

Schabath, Matthew B. "Abstract IA018: Sexual orientation and gender identity (SOGI) collection: Experiences at an NCI-Designated Cancer Center." Cancer Epidemiology, Biomarkers & Prevention 32, no. 12_Supplement (2023): IA018. http://dx.doi.org/10.1158/1538-7755.disp23-ia018.

Full text

Abstract:

Abstract Wide-spread collection of sexual orientation and gender identity (SOGI) data has been a barrier to conduct of research to identify disparities and inequitable cancer care among sexual and gender minority (SGM) populations. Additionally, lack of SOGI data in electronic health records (EHR) renders clinical care teams unable to integrate such information into appropriate and tailored care and treatment plans and may delay the establishment of respectful, affirming, and knowledgeable relationships between patients and their cancer care teams, and the institutions in which they receive he

APA, Harvard, Vancouver, ISO, and other styles

7

Morrill, Susanne, Daniza Mandich, Richard Cartun, and Andrew L. Salner. "Implementation of a high-quality biospecimen program to support molecular medicine." Journal of Clinical Oncology 31, no. 31_suppl (2013): 200. http://dx.doi.org/10.1200/jco.2013.31.31_suppl.200.

Full text

Abstract:

200 Background: The successful implementation of a tumor genomics program relies heavily upon the collection of high quality tumor tissue samples. Although there has been an evolution towards utilizing formalin-fixed paraffin embedded (FFPE) tissue, many research centers continue to rely upon frozen fresh tissue for these types of analyses. A comprehensive effort is required to supply high-volume and high-quality tissue for research. Most community hospitals, even with superb pathology departments, are not well suited to deliver consistent tissue samples without a concerted programmatic effort

APA, Harvard, Vancouver, ISO, and other styles

8

Walker-Mimms, Hannah L., Nicole Londono, Yi Liao, et al. "Abstract 647: FDA approved library screen revealed Ewing and clear cell sarcomas have increased sensitivity to filanesib over other cancer types." Cancer Research 84, no. 6_Supplement (2024): 647. http://dx.doi.org/10.1158/1538-7445.am2024-647.

Full text

Abstract:

Abstract There is a compelling need for the development of more effective and less toxic therapies for patients with Ewing Sarcoma (ES) and Clear Cell Sarcoma (CCS). ES and CCS are characterized by chromosomal translocations which result in two distinct fusion proteins: EWS-ATF1 (t(12;22)(q13;q12)) in CCS and EWS-FLI1 (t(11;22)(q24;q12)) in ES. There is a strong premise that targeting the fusion proteins or their key downstream signaling pathways will be disease modifying and improve outcomes for patients. Preliminary high throughput screening studies using an FDA approved small molecule compo

APA, Harvard, Vancouver, ISO, and other styles

9

Palve, Vinayak C., Hannah L. Walker-Mimms, Ritu Chaudhary, et al. "Abstract 3368: Combination of a chk1/2 dual inhibitor (prexasertib) and gemcitabine reveals a novel intrinsic synergy mechanism in head and neck squamous cell carcinoma." Cancer Research 84, no. 6_Supplement (2024): 3368. http://dx.doi.org/10.1158/1538-7445.am2024-3368.

Full text

Abstract:

Abstract Head and neck squamous cell carcinoma (HNSCC) presents a challenging clinical scenario due to its recurrence propensity despite existing treatments. Altered intrinsic signaling pathways significantly contribute to therapeutic resistance, demanding exploration of novel strategies to induce tumor cell demise. Dysregulated cell cycle and DNA damage repair constitute pivotal events driving HNSCC progression, offering potential therapeutic targets.CHK1 and CHK2, pivotal regulators of the DNA replication checkpoint, are promising targets in HNSCC. The convergence of DNA-damaging agents with

APA, Harvard, Vancouver, ISO, and other styles

10

Strickland-Marmol, Leah B., Andras Khoor, Sandra K. Livingston, and Amyn Rojiani. "Utility of Tissue-Specific Transcription Factors Thyroid Transcription Factor 1 and Cdx2 in Determining the Primary Site of Metastatic Adenocarcinomas to the Brain." Archives of Pathology & Laboratory Medicine 131, no. 11 (2007): 1686–90. http://dx.doi.org/10.5858/2007-131-1686-uottft.

Full text

Abstract:

AbstractContext.—Brain metastases of adenocarcinoma of unknown primary pose a diagnostic dilemma to the surgical pathologist. Although the most common source in these cases is the lung, determining a primary source is difficult on routinely stained slides. Immunohistochemical stain panels including differential cytokeratins, hormone receptors, and breast-specific proteins are commonly used in these cases. Recently, attention has turned to tissue-specific transcription factors, such as thyroid transcription factor 1 (TTF-1) and Cdx2, in the appraisal of metastatic adenocarcinomas.Objective.—To

APA, Harvard, Vancouver, ISO, and other styles

11

Wang, Chao, Jamie Teer, Jiqiang Yao, et al. "280 Both tumor intrinsic and extrinsic factors contribute to TIL resistance in lung cancer patients." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (2020): A305—A306. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0280.

Full text

Abstract:

BackgroundAlthough cancer immunotherapies have achieved great success, many patients either do not respond or initially respond but later relapse. Several resistance mechanisms have been proposed from trials using immune checkpoint inhibitors or CAR-T therapy,1,2 but few studies have been conducted on resistance mechanisms to TIL therapy. In our trial, anti-PD1 refractory lung cancer patients were treated using TIL therapy. Several patients responded while others did not. We hypothesize that both tumor intrinsic and extrinsic factors may contribute to TIL resistance in lung cancer patients.Met

APA, Harvard, Vancouver, ISO, and other styles

12

Powell, Scott A., Chau T. Nguyen, Joy Gaziano, Vicki Lewis, Richard F. Lockey, and Tapan A. Padhya. "Mass Psychogenic Illness Presenting as Acute Stridor in an Adolescent Female Cohort." Annals of Otology, Rhinology & Laryngology 116, no. 7 (2007): 525–31. http://dx.doi.org/10.1177/000348940711600708.

Full text

Abstract:

Objectives: We describe a cohort of patients with an unusual presentation of stridor, their evaluation and management, and their outcome. We review the pertinent English-language literature. Methods: We performed a retrospective review of the records of 12 adolescent patients treated for acute-onset inspiratory stridor at the Departments of Otolaryngology-Head and Neck Surgery and Allergy and Immunology at the University of South Florida and the Department of Speech Pathology at the H. Lee Moffitt Cancer Center and Research Institute. Two additional patients received treatment elsewhere. Demog

APA, Harvard, Vancouver, ISO, and other styles

13

Colin-Leitzinger, Christelle, Daniel Jeong, Mahmoud Abdalah, et al. "Abstract 5886: Pre-treatment adiposity measured by computed tomography and survival of women with high-grade serous ovarian cancer." Cancer Research 82, no. 12_Supplement (2022): 5886. http://dx.doi.org/10.1158/1538-7445.am2022-5886.

Full text

Abstract:

Abstract The association of body mass index (BMI) with survival of women with ovarian cancer remains unclear due to mixed epidemiological evidence. This may be due, in part, to the fact that BMI is an imperfect measure of body fat as BMI does not distinguish weight from lean muscle versus adipose tissue. Here, we investigated the association of adiposity measured by computed tomography (CT) with survival among the most common histotype of ovarian cancer, high-grade serous ovarian cancer (HGSOC). The present study included 383 women diagnosed with HGSOC from 2008 to 2019 who were evaluated at H

APA, Harvard, Vancouver, ISO, and other styles

14

Tan, Chia Jie, Connor Willis, Trang Au, et al. "Survival outcomes of Black/African American (B/AA) patients with HER2-negative (IHC 0, 1+, 2+ and ISH-), advanced breast cancer (HER2-neg aBC) across three academic cancer centers in the United States." JCO Oncology Practice 20, no. 10_suppl (2024): 129. http://dx.doi.org/10.1200/op.2024.20.10_suppl.129.

Full text

Abstract:

129 Background: As B/AA patients are underrepresented in clinical research, data is limited on survival outcomes of B/AA patients with HER2-neg aBC. This study compared survival outcomes of these patients against those of non-B/AA patients. Methods: This was a retrospective cohort study at Huntsman Cancer Institute, H. Lee Moffitt Cancer Centre and Research Institute, and Winthrop P. Rockefeller Cancer Institute. Adult patients diagnosed with HER2-neg aBC from 2010 to 2021 were eligible. Patient data were extracted via chart review, including self-reported race from clinical records. HER2-low

APA, Harvard, Vancouver, ISO, and other styles

15

Peker, Deniz, Yizhou Zhang, Young Yu, et al. "Clinicopathological Characteristics and Clinical Course of CD8 Expressing Primary Cutaneous Peripheral T-Cell Lymphomas (CTCL) - Retrospective Case Study." Blood 118, no. 21 (2011): 5213. http://dx.doi.org/10.1182/blood.v118.21.5213.5213.

Full text

Abstract:

Abstract Abstract 5213 Background: CD8-positive primary cutaneous T cell lymphomas (CTCL) are rare disorders and mainly include primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma (AECTL) and CD8+ variant mycosis fungoides (MF). In contrast to primary cutaneous CD8+ AECTL, which frequently exhibits strikingly aggressive and unfavorable clinical behavior, CD8+ MF shows debatable clinical course, from an indolent to aggressive behavior. As previously reported, the indolent subtype CD8+ MF occur more frequently in pediatric group, while both clinical subtypes have b

APA, Harvard, Vancouver, ISO, and other styles

16

Ammad Ud Din, Mohammad, Todd C. Knepper, Julio C. Chavez, et al. "Clinical Characteristics, Treatment Strategies, and Outcomes for CLL Patients with BTK Mutation; A Single Center Study." Blood 142, Supplement 1 (2023): 1911. http://dx.doi.org/10.1182/blood-2023-179658.

Full text

Abstract:

Background: The population of patients with chronic lymphocytic leukemia (CLL) with disease refractory to Bruton tyrosine kinase inhibitors (BTKi) is growing given the widespread use of these agents. We conducted a single center study to evaluate the disease characteristics, treatment strategies, and outcomes for patients with BTK mutation. Methods: The archives of personalized genetic medicine at the H Lee Moffitt Cancer Center and Research Institute were accessed to identify cases of BTK mutation confirmed by next generation sequencing that were reviewed between 2016-2023. Individual records

APA, Harvard, Vancouver, ISO, and other styles

17

Baz, Rachid, Mohamad Hussein, Daniel J. Lebovic, et al. "Evaluation of Single Agent Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma (NDMM)." Blood 114, no. 22 (2009): 3868. http://dx.doi.org/10.1182/blood.v114.22.3868.3868.

Full text

Abstract:

Abstract Abstract 3868 Poster Board III-804 Introduction Lenalidomide (Len) is an immunomodulatory drug with antitumor effects mediated through activation of T and NK cells as well as modulation of tumor cytokine environment. Currently Len is approved in combination with dexamethasone (dex) for treatment of patients with relapsed myeloma. Interestingly, in NDMM, higher 1 and 2 year survival rates were observed when the dose of dex was reduced compared to standard high dose dexamethasone and Len (Rajkumar et al. 2008). The immune suppressive effects of dex can antagonize Len immunomodulatory ac

APA, Harvard, Vancouver, ISO, and other styles

18

Ammad Ud Din, Mohammad, Katherine Tobon, Julio C. Chavez, et al. "The Real-World Safety and Tolerability of Pirtobrutinib Among Patients with B Cell Lymphomas; A Single Center Experience." Blood 144, Supplement 1 (2024): 6778. https://doi.org/10.1182/blood-2024-208769.

Full text

Abstract:

Background: Pirtobrutinib is an oral highly selective noncovalent Bruton tyrosine kinase inhibitor (BTKi) that has shown promising efficacy in heavily treated patients with relapsed/refractory (R/R) B cell lymphomas. We conducted a single-center retrospective study evaluating the safety and tolerability of pirtobrutinib in the real-world setting. Methods: The data for this study was gathered using the prescription records from the outpatient pharmacy at the H Lee Moffitt Cancer Center and Research Institute. All patients who were prescribed pirtobrutinib from June 1st, 2022 to June 1st, 2024 a

APA, Harvard, Vancouver, ISO, and other styles

19

Cultrera, Jennifer L., Jijun Liu, Idalia Liboy, et al. "A Phase II Study of Gemcitabine, Rituximab, and Oxaliplatin In Combination for Relapsed/Refractory Non-Hodgkin's Lymphomas." Blood 116, no. 21 (2010): 2879. http://dx.doi.org/10.1182/blood.v116.21.2879.2879.

Full text

Abstract:

Abstract Abstract 2879 Background: Non-Hodgkin's Lymphomas (NHL) are heterogeneous group hematologic malignancies. Although diffuse large B-cell lymphoma can be treated effectively with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) there is a relatively high relapse rate requiring alternative chemotherapy regimen. The optimal salvage regimen is not known. Intensive multi-agent chemotherapy in combination with rituximab yield often responses up to 50 to 60% in relapsed/refractory NHL. In this study we sought to evaluate the efficacy of gemcitabine, rituximab and

APA, Harvard, Vancouver, ISO, and other styles

20

TORRESROCA, J., A. CANTOR, S. SHUKLA, et al. "Treatment of intermediate risk prostate cancer with brachytherapy monotherapy: A review of the H Lee Moffitt cancer center experience." International Journal of Radiation OncologyBiologyPhysics 60 (September 2004): S185. http://dx.doi.org/10.1016/s0360-3016(04)01174-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Torres-Roca, J. F., A. B. Cantor, S. Shukla, et al. "Treatment of intermediate risk prostate cancer with brachytherapy monotherapy: A review of the H Lee Moffitt cancer center experience." International Journal of Radiation Oncology*Biology*Physics 60, no. 1 (2004): S185. http://dx.doi.org/10.1016/j.ijrobp.2004.06.117.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Galindo, Carmen Maria Anadon, Xiaoqing Yu, kay Hanggi, et al. "Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T-cells." Journal of Immunology 208, no. 1_Supplement (2022): 63.04. http://dx.doi.org/10.4049/jimmunol.208.supp.63.04.

Full text

Abstract:

Abstract Despite repeated associations between T-cell infiltration and patient outcome, human ovarian cancer remains poorly responsive to immunotherapy. We report that hallmarks of tumor recognition in ovarian cancer-infiltrating T-cells are primarily restricted to tissue-resident memory (TRM) cells. In mouse models we found that TRM T-cells were better than the re-circulating counterpart at controlling tumor growth. Single-cell RNA/TCR/ATAC sequencing of 83,454 CD3+CD8+CD103+CD69+ TRM cells and 24,175 CD3+CD8+CD103− re-circulating TILs showed that progenitor (TCF1low) tissue-resident memory T

APA, Harvard, Vancouver, ISO, and other styles

23

Office, Editorial. "A rare transition of non-Hodgkin lymphoma into classical Hodgkin disease." Advances in Modern Oncology Research 2, no. 5 (2016): 242. http://dx.doi.org/10.18282/amor.v2.i5.178.

Full text

Abstract:

<div>An uncommon case of blood cancer non-Hodg- kin lymphoma developing into classical Hodgkin lymphoma was recently described by researchers from the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida in a case report published in this issue of AMOR.</div><p> </p><p>“Through a series of biopsies, we report a unique case of diffuse large B-cell lymphoma (DLBCL) with stepwise development of classical Hodgkin lymphoma (cHL),” said pathologists Dr. Haipeng Shao and Pardis Vafaii from the Department of Hematopathology and Laboratory Medicine. “To th

APA, Harvard, Vancouver, ISO, and other styles

24

Brent, Hollenbeck. "Commentary on: “Satisfaction with information used to choose prostate cancer treatment.” Gilbert SM, Sanda MG, Dunn RL, Greenfield TK, Hembroff L, Klein E, Saigal CS, Pisters L, Michalski J, Sandler HM, Litwin MS, Wei JT. H. Lee Moffitt Cancer Center, Tampa, Florida; Department of Urology, Emory University, Atlanta, Georgia; Department of Urology, University of Michigan, Ann Arbor, Michigan; Department of Psychiatry and Public Health Institute, University of California-San Francisco, California; Institute for Public Policy and Social Research, Michigan State University, Lansing, Michigan; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio; Department of Urology and Department of Health Policy and Management, University of California-Los Angeles, Los Angeles, California; Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri; Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California." Urologic Oncology: Seminars and Original Investigations 34, no. 5 (2016): 247–48. http://dx.doi.org/10.1016/j.urolonc.2015.02.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Strosberg, Jonathan R., Asima Cheema, Jill Weber, Gang Han, Domenico Coppola, and Larry K. Kvols. "Prognostic Validity of a Novel American Joint Committee on Cancer Staging Classification for Pancreatic Neuroendocrine Tumors." Journal of Clinical Oncology 29, no. 22 (2011): 3044–49. http://dx.doi.org/10.1200/jco.2011.35.1817.

Full text

Abstract:

Purpose The American Joint Committee on Cancer (AJCC) staging manual (seventh edition) has introduced its first TNM staging classification for pancreatic neuroendocrine tumors (NETs) derived from the staging algorithm for exocrine pancreatic adenocarcinomas. This classification has not yet been validated. Methods Patients with pancreatic NETs treated at the H. Lee Moffitt Cancer Center between 1999 and 2010 were assigned a stage (I to IV) based on the new AJCC classification. Kaplan-Meier analyses for overall survival (OS) were performed based on age, race, histologic grade, incidental diagnos

APA, Harvard, Vancouver, ISO, and other styles

26

Elfenbein, Gerald J. "Optimizing recovery from aplasia after high-dose therapy and hematopoietic stem cell transplantation." Journal of Oncology Pharmacy Practice 2, no. 1_suppl (1996): 4–10. http://dx.doi.org/10.1177/1078155296002001s02.

Full text

Abstract:

Objective. Discussion of the roles of hematopoietic growth factors and the role of stem cells in shortening aplasia after transplant. In addition, the role of the treatment regimen in determining the length of aplasia. Data Sources. A series of original research stud ies from H. Lee Moffitt Cancer center which was published from 1993 to the present. In addition, selected references were reviewed and quoted to support selective arguments. Study Selection. Since 1989 data from four allo cated, parallel, high-dose phase I/II trials conducted at H. Lee Moffitt Cancer Center, Tampa, Fla and include

APA, Harvard, Vancouver, ISO, and other styles

27

Santillan, Alfredo A., Jane L. Messina, Suroosh S. Marzban, Gema Crespo, Vernon K. Sondak, and Jonathan S. Zager. "Pathology Review of Thin Melanoma and Melanoma in Situ in a Multidisciplinary Melanoma Clinic: Impact on Treatment Decisions." Journal of Clinical Oncology 28, no. 3 (2010): 481–86. http://dx.doi.org/10.1200/jco.2009.24.7734.

Full text

Abstract:

Purpose Patients with thin melanoma (≤ 1.0 mm) and melanoma in situ (MIS) represent the majority of newly diagnosed melanoma. We estimated the impact of expert review of outside pathology material on the staging and thus treatment decisions affecting patients referred to a multidisciplinary clinic with early-stage melanoma. Patients and Methods We studied patients with a diagnosis of thin melanoma or MIS referred to H. Lee Moffitt Cancer Center from 2006 to 2009. After comparing the referring laboratory and in-house dermatopathologic interpretations, we calculated any differences in diagnosis

APA, Harvard, Vancouver, ISO, and other styles

28

Simon, G. R., M. J. Schell, M. Begum, et al. "Evidence for long-term survival in a sizeable proportion of good performance status (PS) patients (pts) with advanced non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 27, no. 15_suppl (2009): e19016-e19016. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e19016.

Full text

Abstract:

e19016 Background: Approximately 40% of NSCLC pts present with metastatic disease where treatment is considered palliative. Here we examine whether prolonged survival is possible in a sizeable proportion of NSCLC pts with good PS and stage IV disease particularly given the availability of personalized chemotherapy approaches. Methods: NSCLC pts with stage IV disease and an ECOG PS of 0/1 were prospectively accrued to four phase II clinical trials, at the H. Lee Moffitt Cancer Center and treated with the following regimens; Trial A) carboplatin/gemcitabine first-line followed by docetaxel secon

APA, Harvard, Vancouver, ISO, and other styles

29

Ashraf, Noman, Saqib Razzaque, Jill M. Weber, Mokenge Peter Malafa, and Richard D. Kim. "Does 18-fluorodeoxyglucose (FDG) uptake by positron emission tomography/computed tomography (PET/CT) predict survival in advanced pancreatic cancer? A single-institution experience." Journal of Clinical Oncology 30, no. 15_suppl (2012): e14715-e14715. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14715.

Full text

Abstract:

e14715 Background: Pancreatic cancer is associated with a poor prognosis. Histological grade, stage and serum tumor markers are well established prognostic factors for survival. Some studies suggest that 18-fluorodeoxyglucose (FDG) uptake by positron emission tomography/computed tomography (PET/CT) correlates with survival in pancreatic cancer. In this study, we aimed to determine whether standardized uptake value (SUV), a measure of FDG uptake by fusion PET/CT, had prognostic significance in patients with advanced pancreatic cancer. Methods: Using a comprehensive pancreatic cancer database at

APA, Harvard, Vancouver, ISO, and other styles

30

Pina, Yolanda, Nam Tran, Neha Verma, et al. "NCMP-21. IMMUNE-RELATED ACUTE MOTOR AXONAL NEUROPATHY: A SMALL CASE SERIES AND REVIEW OF THE LITERATURE." Neuro-Oncology 23, Supplement_6 (2021): vi151. http://dx.doi.org/10.1093/neuonc/noab196.592.

Full text

Abstract:

Abstract BACKGROUND Immunotherapy revolutionized cancer treatment in the past decade, with a significant increased survival in patients with solid tumors. However, immune checkpoint inhibitors (ICIs) have been associated with a growing number of neurotoxicities, some of which can be fatal if not recognized and treated promptly. Some of these neurotoxicities include very uncommon syndromes like Acute Motor Axonal Neuropathy (AMAN). Herein we present four oncological cases of patients who underwent immunotherapy and developed AMAN. METHODS Four patients were diagnosed with immune-related AMAN be

APA, Harvard, Vancouver, ISO, and other styles

31

Martino, M. A., K. Patrick, R. Wenham, et al. "The impact of optimal (<1cm) surgical debulking on survival at the time of recurrence in patients with uterine leiomyosarcoma (LMS)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 16067. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.16067.

Full text

Abstract:

16067 Objective: Uterine leiomyosarcoma (LMS) is an uncommon female malignancy with limited treatment options. To evaluate whether there exists a role for surgery at the time of recurrence, we performed an outcomes analysis from over 25 years of treating LMS at a single institution. Methods: Patients with uterine leiomyosarcoma who presented for treatment at the H. Lee Moffitt Cancer Center from 1981–2005 were identified from the cancer registry database. Patients who underwent surgery (with or without adjuvant treatment) at the time of first recurrence were compared to those patients who did

APA, Harvard, Vancouver, ISO, and other styles

32

Pina, Y., N. Tran, P. Forsyth, S. Mokhtari, and E. Peguero. "P08.01 Immune-Related Acute Motor Axonal Neuropathy: A Small Case Series and Review of the Literature." Neuro-Oncology 23, Supplement_2 (2021): ii26. http://dx.doi.org/10.1093/neuonc/noab180.088.

Full text

Abstract:

Abstract BACKGROUND Immunotherapy have revolutionized cancer treatment in the past decade, with a significant increased survival in patients with solid tumors. However, the use of immune checkpoint inhibitors (ICIs) has been associated with a growing number of neurotoxicities, some of which can be fatal if not recognized and treated promptly. Some of these neurotoxicities include very uncommon syndromes like Acute Motor Axonal Neuropathy (AMAN). Herein we present four oncological cases of patients who underwent immunotherapy and developed AMAN. METHODS Four patients were diagnosed with immune-

APA, Harvard, Vancouver, ISO, and other styles

33

Patel, Jolly, Mayer N. Fishman, and Dawn Goetz. "High-dose bolus interleukin-2: Correlating response rate with number of doses received." Journal of Clinical Oncology 31, no. 6_suppl (2013): 452. http://dx.doi.org/10.1200/jco.2013.31.6_suppl.452.

Full text

Abstract:

452 Background: Administration of high-dose interleukin-2 (IL-2) in metastatic renal cell carcinoma (MRCC) has higher response and survival rates when compared to low dose or subcutaneous administration. In patients who achieve a response, it may be at the expense of more toxicity risk, from more doses. The association of the major response rate with the number of high dose boluses or cumulative dose received is of interest. The primary objective of this study is to evaluate a direct correlation with response and cumulative dose or the total number of doses received. Methods: A retrospective c

APA, Harvard, Vancouver, ISO, and other styles

34

Costa, Ricardo L., Jennifer A. Childress, Edith Abraham, et al. "Phase 1 dose-escalation, dose-expansion trial of intratumoral HER2- and HER3-primed dendritic cells injections for the treatment of early-stage TNBC and HR low positive breast cancer: DecipHER trial." Journal of Clinical Oncology 41, no. 16_suppl (2023): TPS629. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps629.

Full text

Abstract:

TPS629 Background: Patients with breast cancers (BCs) harboring low expression of hormone receptors (HRs) and human epidermal growth factor receptor-2 (HER2) have poor outcomes. Results from the KEYNOTE-522 trial showed that activation of the immune system using a PD1/PD-L1-targeted approach improves outcomes of patients with these high-risk tumors. Antigen-presenting cells (eg, dendritic cells [DCs]) are pivotal for robust cytotoxic responses due to broader activation of the adaptive immune system (ie, CD4+ and CD8+ Th1) against tumor-associated antigens (ie, HER2 or HER3) expressed by high-r

APA, Harvard, Vancouver, ISO, and other styles

35

Ashraf, Noman, Saqib Razzaque, Jill M. Weber, Mokenge Peter Malafa, and Richard D. Kim. "Does 18-fluorodeoxyglucose (FDG) uptake by positron emission tomography/computed tomography (PET/CT) predict survival in advanced pancreatic cancer? A single-institution experience." Journal of Clinical Oncology 30, no. 4_suppl (2012): 351. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.351.

Full text

Abstract:

351 Background: Pancreatic cancer is associated with a poor prognosis. Histological grade, stage and serum tumor markers are well established prognostic factors for survival. Some studies suggest that 18-fluorodeoxyglucose (FDG) uptake by positron emission tomography/computed tomography (PET/CT) correlates with survival in pancreatic cancer. In this study, we aimed to determine whether standardized uptake value (SUV), a measure of FDG uptake by fusion PET/CT, had prognostic significance in patients with advanced pancreatic cancer. Methods: Using a comprehensive pancreatic cancer database at H.

APA, Harvard, Vancouver, ISO, and other styles

36

Dunham, Alden J., Steven Benyahia, Bhargav Kansara, et al. "The metabolic profiles of patients with autologous hematopoietic stem cell transplantation with graft versus host disease." Journal of Clinical Oncology 42, no. 16_suppl (2024): e24010-e24010. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e24010.

Full text

Abstract:

e24010 Background: Graft versus host disease (GvHD) is a serious inflammatory complication of hematopoietic stem cell transplant (HSCT) and a leading contributor to morbidity and mortality in HSCT patients. Previous studies have identified increased risk of cardiovascular death in HSCT patients who develop GvHD and characterized echocardiographic changes associated with chronic GvHD. However, details of the metabolic derangements in HSCT patients who develop GvHD remain poorly studied. Methods: This is a retrospective study of patients who underwent HSCT at H. Lee Moffitt Cancer Center and lat

APA, Harvard, Vancouver, ISO, and other styles

37

Ahmed, Kamran A., Youngchul Kim, Avan Armaghani, et al. "Abstract OT3-19-01: Phase II Study of Screening Brain MRIs in Stage IV Breast Cancer." Cancer Research 83, no. 5_Supplement (2023): OT3–19–01—OT3–19–01. http://dx.doi.org/10.1158/1538-7445.sabcs22-ot3-19-01.

Full text

Abstract:

Abstract Background: As systemic therapy improves, there has been an increasing number of breast cancer patients who develop brain metastasis. Screening of asymptomatic stage IV breast cancer patients with brain MRIs is not currently recommended by the National Comprehensive Cancer Network (NCCN) Guidelines. Retrospective reports suggest breast cancer patients are more likely to present with more advanced central nervous system disease at the time of brain metastasis diagnosis compared to melanoma and non-small cell lung cancer (NSCLC) patients. This may be in part due to routine screening rec

APA, Harvard, Vancouver, ISO, and other styles

38

Innamarato, Patrick, Shari Pilon-Thomas, Jennifer Morse, et al. "585 Intralesional injection of rose bengal improves the efficacy of gemcitabine chemotherapy against pancreatic cancer." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (2020): A620. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0585.

Full text

Abstract:

BackgroundChemotherapy regimens that include gemcitabine are considered standard of care in patients with advanced pancreatic ductal adenocarcinoma (PDAC). However, most patients with PDAC die within 2 years of diagnosis, even with these standard of care regimens. In this study, we explored the ability of intratumoral injections of PV-10, a 10% solution of rose bengal, to induce lesion-specific ablation and control of metastatic pancreatic tumors in a murine model.MethodsPV-10 was cultured with human pancreatic cancer cell lines overnight and cell death was measured via Annexin-V and DAPI stai

APA, Harvard, Vancouver, ISO, and other styles

39

Strobl, Maximilian A., Alexandra L. Martin, Christopher Gallagher, et al. "Abstract 5694: Adaptive treatment scheduling of PARP inhibitors in ovarian cancer: Using mathematical modeling to assess clinical feasibility and estimate potential benefits." Cancer Research 83, no. 7_Supplement (2023): 5694. http://dx.doi.org/10.1158/1538-7445.am2023-5694.

Full text

Abstract:

Abstract PARP inhibitors (PARPis) are revolutionizing the treatment of ovarian cancer. Yet for many patients these improvements come at the cost of physical and financial toxicity and responses are typically temporary due to emerging drug resistance. A growing body of pre-clinical and clinical work suggests that when cure is unlikely, it is possible to delay progression and reduce drug use through patient-specific drug scheduling. So-called 'adaptive therapy' dynamically adjusts treatment to preserve drug-sensitive cells which interfere with resistant cells through competition. In a prior stud

APA, Harvard, Vancouver, ISO, and other styles

40

Sonpavde, Guru P., Carlos A. Alemany, Wassim Mchayleh, et al. "Phase II trial of lurbinectedin combined with avelumab as maintenance therapy for metastatic urothelial carcinoma with stable or responding disease following platinum-based chemotherapy." Journal of Clinical Oncology 41, no. 6_suppl (2023): TPS590. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.tps590.

Full text

Abstract:

TPS590 Background: Maintenance avelumab following stable/responding disease after 4-6 cycles of platinum-based chemotherapy is a conventional first-line therapy for metastatic urothelial carcinoma (mUC). Given the attrition of patients between lines of systemic therapy, there is a role for extending the benefits of maintenance avelumab by combinations with tolerable and active agents. Lurbinectedin (Lurbi) is an alkylating agent and selective inhibitor of oncogenic transcription. Lurbi is approved by the US FDA for treating small cell lung cancer with progression on platinum-based chemotherapy

APA, Harvard, Vancouver, ISO, and other styles

41

Hamaidi, Imene, Anders Berglund, Matthew Mills, Ryan Putney, James Mule, and Sungjune Kim. "907 Modulation of tumor immunogenicity by DNA methylation of immune synapse genes in cancers." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (2021): A952. http://dx.doi.org/10.1136/jitc-2021-sitc2021.907.

Full text

Abstract:

BackgroundCancer immunotherapy represents a major paradigm shift in cancer care. Despite such breakthrough, majority of cancer patients remains refractory to existing immunotherapeutic modalities highlighting the inherent capacity of tumors to escape immunosurveillance mechanisms. Frequently, cancer cells utilize the epigenetic machinery to silence tumor suppressors or activate oncogenes for survival and proliferation. Likewise, tumor cells might employ the epigenetic reprogramming of immune-related pathways to evade the immune system. Methylation is one of the major epigenetic mechanisms modu

APA, Harvard, Vancouver, ISO, and other styles

42

Renatino-Canevarolo, Rafael, Mark B. Meads, Maria Silva, et al. "Dynamic Epigenetic Landscapes Define Multiple Myeloma Progression and Drug Resistance." Blood 136, Supplement 1 (2020): 32–33. http://dx.doi.org/10.1182/blood-2020-142872.

Full text

Abstract:

Multiple myeloma (MM) is an incurable cancer of bone marrow-resident plasma cells, which evolves from a premalignant state, MGUS, to a form of active disease characterized by an initial response to therapy, followed by cycles of therapeutic successes and failures, culminating in a fatal multi-drug resistant cancer. The molecular mechanisms leading to disease progression and refractory disease in MM remain poorly understood. To address this question, we have generated a new database, consisting of 1,123 MM biopsies from patients treated at the H. Lee Moffitt Cancer Center. These samples ranged

APA, Harvard, Vancouver, ISO, and other styles

43

Lebovic, Daniel J., Rachid Baz, Melissa Alsina, et al. "Cytogenetics and Clinical Outcomes of Plasma Cell Leukemia Patients: A Single Institution Experience." Blood 114, no. 22 (2009): 4932. http://dx.doi.org/10.1182/blood.v114.22.4932.4932.

Full text

Abstract:

Abstract Abstract 4932 Introduction Plasma cell leukemia (PCL) is a rare, poorly understood and clinically aggressive plasma cell dyscrasia that can originate from multiple myeloma (sPCL) or de novo as primary PCL (pPCL). Historically, median survival of patients with PCL has been reported to be 1 and 11 months for patients with secondary and primary PCL, respectively (Tiedemann, Leukemia 2008). The impact of novel agents and transplantation strategies on outcomes of patients with PCL remains unclear. In addition, few have reported extensively on the cytogenetics abnormalities seen in patients

APA, Harvard, Vancouver, ISO, and other styles

44

Cluzeau, Thomas, Kathy L. McGraw, Brittany Irvine, et al. "The Proinflammatory Protein S100A9 Suppresses Erythropoietin Elaboration in Patients with Myelodysplastic Syndromes." Blood 126, no. 23 (2015): 355. http://dx.doi.org/10.1182/blood.v126.23.355.355.

Full text

Abstract:

Abstract Introduction: Accumulating evidence implicates innate immune activation in the pathobiology of myelodysplastic syndromes (MDS) and its inflammatory bone marrow microenvironment. Excess elaboration of S100A9 accompanied by secondary induction of TNFα and IL-1β, characterize the inflammatory milieu found in lower risk MDS. Erythroid stimulating agents (ESA) and lenalidomide (LEN) are erythropoietic promoters with known anti-inflammatory properties. To date, the role of such inflammation parameters in endogenous erythropoietin (Epo) regulation and response to such treatments has not been

APA, Harvard, Vancouver, ISO, and other styles

45

Ades, Lionel, Mikkael A. Sekeres, Alice Wolfromm, et al. "Prognostic Factors of Response and Survival in CMML Patients Treated with Azacitidine (AZA)." Blood 118, no. 21 (2011): 1726. http://dx.doi.org/10.1182/blood.v118.21.1726.1726.

Full text

Abstract:

Abstract Abstract 1726 Background: Treatment of CMML remains a clinical challenge, with no drug demonstrating clear clinical benefit. AZA yielded a survival benefit in higher risk MDS in a study that included few patients with CMML (AZA 001 trial, Lancet Oncol, 2009). Several small series of CMML treated by Decitabine (Wijermans, Leuk Res. 2008, Aribi A, Cancer. 2007 and Kantarjian H, Blood. 2007) and AZA (Scott, Br J Haematol. 2010) have been reported, but numbers were small with heterogeneous risk factors. Methods: A cohort of CMML pts (according to WHO classification) treated with AZA in 3

APA, Harvard, Vancouver, ISO, and other styles

46

Lancet, Jeffrey E., Jorge E. Cortes, Donna E. Hogge, et al. "Phase 2B Randomized Study of CPX-351 Vs. Cytarabine (CYT) + Daunorubicin (DNR) (7+3 Regimen) In Newly Diagnosed AML Patients Aged 60–75." Blood 116, no. 21 (2010): 655. http://dx.doi.org/10.1182/blood.v116.21.655.655.

Full text

Abstract:

Abstract Abstract 655 Introduction: CPX-351 is a liposomal formulation encapsulating CYT and DNR at a 5:1 molar ratio that maximizes synergy. CPX-351 was well tolerated and demonstrated markedly prolonged plasma half-life for CYT (t1/2=31.1 hours) and DNR (t1/2=21.9 hours) in Phase 1. Responses (CR + CRp) were noted in patients with prior 7+3 exposure including some with multiple relapses and primary induction failure. A Phase 2 study using 2:1 randomization to demonstrate efficacy and safety of CPX-351 versus conventional 7+3 regimen is summarized here. Methods: Subjects with de novo or 2o AM

APA, Harvard, Vancouver, ISO, and other styles

47

Fishman, Brooke, Elizabeth Crenshaw, Megan Finch, and Neeharika Srivastava Makani. "Abstract P5-12-27: HER2 Status and Clinical Outcomes in Breast Cancer: A Retrospective Analysis." Clinical Cancer Research 31, no. 12_Supplement (2025): P5–12–27—P5–12–27. https://doi.org/10.1158/1557-3265.sabcs24-p5-12-27.

Full text

Abstract:

Abstract Background: HER2 status is a prognostic marker in breast cancer (BC). Studies have demonstrated that patients with high HER2 expression have poor prognosis compared to HER2 negative (HER2-neg) disease.(1,2) Currently, BC is classified into categories based on HER2 expression and hormone receptor status (estrogen receptor (ER) and progesterone receptor (PR)). Previously, HER2 status was defined as HER2-neg or HER2- high; however, in 2022, the FDA approved fam-trastuzumab deruxtecan-nxki in the management of metastatic HER2-low BC.3 Though publications from large international academic

APA, Harvard, Vancouver, ISO, and other styles

48

Chowdhury, Uttam. "Regulation of transgelin and GST-pi proteins in the tissues of hamsters exposed to sodium arsenite." International Journal of Toxicology and Toxicity Assessment 1, no. 1 (2021): 1–8. http://dx.doi.org/10.55124/ijt.v1i1.49.

Full text

Abstract:

Hamsters were exposed to sodium arsenite (173 mg As/L) in drinking water for 6 days. Equal amounts of proteins from urinary bladder or liver extracts of control and arsenic-treated hamsters were labeled with Cy3 and Cy5 dyes, respectively. After differential in gel electrophoresis and analysis by the DeCyder software, several protein spots were found to be down-regulated and several were up regulated. Our experiments indicated that in the bladder tissues of hamsters exposed to arsenite, transgelin was down-regulated and GST-pi was up-regulated. The loss of transgelin expression has been report

APA, Harvard, Vancouver, ISO, and other styles

49

"Department of Anatomic Pathology H. Lee Moffitt Cancer Center & Research Institute." Cancer Control 22, no. 2 (2015): 136–37. http://dx.doi.org/10.1177/107327481502200202.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Jones, Nat C., Monica E. Reyes, Gwendolyn P. Quinn, and Matthew B. Schabath. "Survey of Principal Investigators in Biobanking: Knowledge, Attitudes, and Research Behaviors About Transgender and Gender-Diverse Patients." JCO Oncology Practice, June 11, 2020, OP.20.00193. http://dx.doi.org/10.1200/op.20.00193.

Full text

Abstract:

PURPOSE: Biobanks usually do not collect transgender and gender-diverse (TGD) demographic information, hindering research on cancer risk and biological effects related to gender-affirming interventions. METHODS: In August 2019, 172 scientists involved in biobanking research at a single institution (H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL) were invited to complete a survey measuring knowledge and attitudes about TGD health and research practices. Quantitative and qualitative analyses were performed. RESULTS: Among 47 respondents, there was high agreement (77%) regarding t

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!